<DOC>
	<DOCNO>NCT03093883</DOCNO>
	<brief_summary>The aim pharmacokinetic study assess bioequivalence generic Ferrinemia® Iron Sucrose injection solution 20 mg/mL manufacture Help S.A. , Greece ( test product ) , Venofer® Iron Sucrose injection solution 20 mg/mL manufacture Vifor AG , Switzerland ( reference product ) . Both formulation contain iron active ingredient . Intravenous iron sucrose primarily indicate treatment iron deficiency anemia adult patient .</brief_summary>
	<brief_title>Bioequivalence Study Comparing Single Dose Ferrinemia® Injection With Single Dose Venofer® Injection Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male healthy volunteer within age range 18 45 year ( inclusive ) Comprehension nature purpose study willingness comply requirement entire procedure Subjects good health base previous medical history , physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory test assess time screen Ferritin level ≥ 30 µg/l Transferrin ≥ 200 mg/dl Hemoglobin level ≥ 13.5 g/dl Subjects BMI &lt; 19 kg/m2 &gt; 30 kg/m2 History iron deficiency within six month prior screen History anemia within 1 year prior screen Presence iron overload disturbance utilization iron History evidence allergy hypersensitivity active substance Iron Sucrose test reference product , finished test reference product excipients ( water injection , sodium hydroxide ) Hypersensitivity parenteral iron product Use iron supplement iron contain herbal nutritional supplement within last three month prior start study History difficulty donate blood difficulty accessibility vein leave right arm Donation blood ( one unit 350 mL ) within last three month prior first dose administration study drug Evidence active suspect cancer , history malignancy within last 2 year , exception patient basal cell carcinoma excise cured History systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) 6 month prior first dose study drug expectation treatment need time study History bleeding disorder anticoagulant use History evidence chronic pulmonary cardiovascular disease associate functional limitation History uncontrolled severe seizure disorder Any sign acute infection inflammation History evidence severe illness , condition would make subject opinion investigator , unsuitable study . Any clinically significant abnormal laboratory value laboratory evaluation , medical history physical examination screen Positive HIV/HBV/HCV serology test time screen visit Abnormal 12lead ECG time screen consider clinically significant History presence severe medical treated allergy immune inflammatory condition ( eg . systemic lupus erythematosus , rheumatoid arthritis ) History atopic allergy associate severe asthma Recent history ongoing kidney liver dysfunction Any major illness last three month significant ongoing chronic medical illness Subjects regularly use 2 unit alcohol per day ( one unit alcohol equal ½ liter beer , 200 mL wine 50 mL spirit ) evidence Cocaine , Amphetamines , Methformin , THC , Methadone , MDMA , Morphine , Barbiturates , Benzodiazepines Tricyclic antidepressant urine screen ) Heavy smoker ( &gt; 10 cigarettes/day ) last three month prior start study Any concomitant medication ( except paracetamol ) within last two week , include overthecounter herbal product , prior receive dose study medication Participation clinical trial within last one month Subjects consider investigator noncompliant unlikely complete study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>